CLINICAL TRIALS PROFILE FOR ACCUPRIL
✉ Email this page to a colleague
All Clinical Trials for ACCUPRIL
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00269243 ↗ | Management With Accupril Post Bypass Graft | Completed | Pfizer | Phase 4 | 1999-11-01 | Angiotensin converting enzyme (ACE) inhibitors have been shown to improve survival and to reduce the risk of cardiovascular events in some groups of patients following myocardial infarction. This study is designed to test whether early initiation (≤7 days) of an ACE inhibitor post-coronary artery bypass graft (CABG), would reduce cardiovascular events. The trial was a double-blind, placebo controlled study of 2,553 patients randomly assigned to quinapril, target dose 40 mg daily or placebo, followed up to 43 months. |
| NCT00269243 ↗ | Management With Accupril Post Bypass Graft | Completed | Montreal Heart Institute | Phase 4 | 1999-11-01 | Angiotensin converting enzyme (ACE) inhibitors have been shown to improve survival and to reduce the risk of cardiovascular events in some groups of patients following myocardial infarction. This study is designed to test whether early initiation (≤7 days) of an ACE inhibitor post-coronary artery bypass graft (CABG), would reduce cardiovascular events. The trial was a double-blind, placebo controlled study of 2,553 patients randomly assigned to quinapril, target dose 40 mg daily or placebo, followed up to 43 months. |
| NCT00438113 ↗ | Atrial Substrate Modification With Aggressive Blood Pressure Lowering to Prevent AF | Completed | Nova Scotia Health Research Foundation | Phase 4 | 2009-12-01 | Atrial fibrillation (AF) is a very common arrhythmia causing many symptoms resulting in numerous hospitalizations. Catheter ablation is a technique that has evolved significantly to improve symptomatic recurrences, but does not offer a 100% cure rate. We hypothesize that the use of aggressive BP lowering will reduce the rate of recurrent AF after catheter ablation for AF. We plan a randomized clinical trial of aggressive BP lowering versus standard BP control to investigate this. |
| NCT00438113 ↗ | Atrial Substrate Modification With Aggressive Blood Pressure Lowering to Prevent AF | Completed | Nova Scotia Health Authority | Phase 4 | 2009-12-01 | Atrial fibrillation (AF) is a very common arrhythmia causing many symptoms resulting in numerous hospitalizations. Catheter ablation is a technique that has evolved significantly to improve symptomatic recurrences, but does not offer a 100% cure rate. We hypothesize that the use of aggressive BP lowering will reduce the rate of recurrent AF after catheter ablation for AF. We plan a randomized clinical trial of aggressive BP lowering versus standard BP control to investigate this. |
| NCT00649103 ↗ | Fasting Study of Quinapril Hydrochloride Tablets 40 mg and Accupril® Tablets 40 mg | Completed | Mylan Pharmaceuticals | Phase 1 | 2002-12-01 | The objective of this study was to investigate the bioequivalence of Mylan quinapril hydrochloride 40 mg tablets compared to Parke-Davis Accupril® 40 mg tablets following a single, oral 40 mg (1 x 40 mg) dose under fasting conditions. |
| NCT00649649 ↗ | Food Study of Quinapril Hydrochloride Tablets 40 mg and Accupril® Tablets 40 mg | Completed | Mylan Pharmaceuticals | Phase 1 | 2002-12-01 | The objective of this study was to investigate the bioequivalence of Mylan quinapril hydrochloride 40 mg tablets compared to Parke-Davis Accupril® 40 mg tablets following a single, oral 40 mg (1 x 40 mg) dose under fed conditions. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for ACCUPRIL
Condition Name
Clinical Trial Locations for ACCUPRIL
Trials by Country
Clinical Trial Progress for ACCUPRIL
Clinical Trial Phase
Clinical Trial Sponsors for ACCUPRIL
Sponsor Name
